Emerging Insights into Fabry Disease: Pathophysiology, Diagnosis, and Multidisciplinary Management Approaches

Mohammed Ziad Aldaajani[1], Abdulmajeed Muhayya Almutairi[1]*, Eissa Homuday Almuteriee[1], Abdullah Saleh Almorshed[1], Abdullah Abdulrahman Alrbian[1], Majed Suliman Alwalie[1], Adel Lafi Alharbi[1], Fahad Hamdi Khalif ALAnazi[1], Maha Mahdi Alanazi[1], Saleh Ali Saleh Al Salloum[1], Turki Suleiman Aqeel Al-Shammari[1], Abdulellah Abdulqader Kassar[1], Badi Talea Alharbi[1], Sarah Rakad Karim Al-Shammari[1]

Abstract

Background: Fabry disease (FD) is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme alpha-galactosidase A (α-Gal A), leading to the accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3), in lysosomes. This accumulation results in multisystemic dysfunction, affecting primarily the renal, cardiovascular, and neurological systems. The disease presents with a spectrum of clinical manifestations, ranging from mild to severe, and poses a diagnostic challenge due to its overlap with more common conditions. Early identification is crucial for effective management. Methods: This review synthesizes current literature on Fabry disease, focusing on its pathophysiology, clinical presentation, diagnostic approaches, and therapeutic strategies. Genetic testing, biomarker assays, and enzyme replacement therapy (ERT) are discussed as essential diagnostic and treatment tools. Recent advancements in therapies, including gene therapy and substrate reduction, are explored. Results: Fabry disease manifests with a range of symptoms including neuropathic pain, angiokeratomas, gastrointestinal issues, renal complications, and cardiac hypertrophy. Females, due to X-chromosome inactivation, present with variable symptoms, while males typically exhibit more severe manifestations. Early diagnosis through genetic testing and biomarkers, such as plasma globotriaosylsphingosine (lyso-Gb3), has enhanced diagnostic accuracy. ERT, although effective in slowing disease progression, remains non-curative. Emerging therapies, including gene therapy, show promise in addressing the disease's underlying causes and improving long-term outcomes. Conclusion: Fabry disease is a complex, systemic disorder that requires a multidisciplinary approach for diagnosis and management. Genetic analysis, enzyme assays, and biomarkers are crucial for accurate diagnosis, while ERT remains the cornerstone of treatment. Despite therapeutic advancements, there remains an unmet need for curative treatments. Early diagnosis and intervention are key to improving patient outcomes and preventing irreversible organ damage. Continued research into novel therapies and diagnostic tools is essential to enhance care for individuals affected by Fabry disease.

Keywords: Fabry disease, Lysosomal storage disorder, Alpha-galactosidase A, Enzyme replacement therapy, Multisystemic complications

Significance | This review highlights Fabry disease's pathophysiology, diagnostic challenges, and evolving therapeutic strategies to improve patient outcomes globally.

*Correspondence. Abdulmajeed Muhayya Almutairi, stry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia
E-mail: almutairia13@mngha.med.sa

Editor Md Shamsuddin Sultan Khan And accepted by the Editorial Board January 15, 2024 (received for review November 22, 2023)

Introduction

Fabry disease is a rare, X-linked lysosomal storage disorder characterized by deficient activity of the enzyme alpha-

Author Affiliation.
[1] Ministry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia.

Please Cite This:
Aldaajani, M. Z., Almutairi, A. M., Almuteriee, E. H., Almorshed, A. S., Alrbian, A. A., Alwalie, M. S., Alharbi, A. L., ALAnazi, F. H. K., Alanazi, M. M., Salloum, S. A. S. A., Al-Shammari, T. S. A., Kassar, A. A., Alharbi, B. T., Al-Shammari, S. R. K. (2024). "Emerging Insights into Fabry Disease: Pathophysiology, Diagnosis, and Multidisciplinary Management Approaches", Journal of Angiotherapy, 8(1),1-8,10085

galactosidase A (α-Gal A). This enzymatic deficit leads to the progressive accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids within lysosomes, resulting in multisystemic dysfunction (Ortiz et al., 2018). Affecting both males and females, Fabry disease presents a wide spectrum of clinical manifestations, ranging from mild symptoms to severe systemic complications, depending on the specific mutation and residual enzyme activity (Arends et al., 2017). Early identification and intervention are essential to mitigate disease progression and improve patient outcomes (Baig et al., 2019; Bokhari et al., 2023).

The disorder typically manifests during childhood or adolescence, particularly in males with the classic phenotype, who experience severe symptoms such as neuropathic pain, angiokeratomas, corneal opacities, and gastrointestinal disturbances (Ortiz et al., 2018; Sweet et al., 2018). In contrast, females often exhibit variable clinical presentations due to X-chromosome inactivation, ranging from asymptomatic carriers to individuals with significant organ involvement (Lenders et al., 2016). Commonly affected systems include the renal, cardiovascular, and central nervous systems, leading to complications such as proteinuria, renal failure, cardiac hypertrophy, arrhythmias, and cerebrovascular events (Wanner et al., 2018; Ersözlü et al., 2018; Siegenthailer et al., 2017). These manifestations underscore the systemic nature of Fabry disease and its profound impact on quality of life and life expectancy (Chan & Adam, 2018) (Table 3).

A significant diagnostic challenge lies in the phenotypic overlap between Fabry disease and more prevalent conditions, such as hypertension, diabetes, or ischemic heart disease (Wasserstein et al., 2019). Consequently, Fabry disease remains underdiagnosed and often misdiagnosed, delaying appropriate management (Schuller et al., 2018). Advances in genetic testing and biomarker assays, such as plasma globotriaosylsphingosine (lyso-Gb3), have greatly enhanced diagnostic accuracy, enabling the identification of pathogenic mutations and atypical presentations (Arends et al., 2017; Wanner et al., 2018). These tools are crucial for early diagnosis, especially in patients presenting with unexplained organ dysfunction or a family history suggestive of Fabry disease (Ortiz et al., 2018; Bokhari et al., 2023).

The pathophysiology of Fabry disease highlights the intricate relationship between genetic mutations and their clinical consequences. The progressive accumulation of Gb3 within endothelial cells, cardiomyocytes, renal epithelial cells, and neurons initiates a cascade of cellular dysfunction and tissue damage (Del Pino et al., 2018). This systemic lipid deposition contributes to vascular inflammation, fibrosis, and ischemia, which underlie the diverse clinical manifestations (Fukuda et al., 2017). Insights into these mechanisms have informed the development of targeted therapies, such as enzyme replacement therapy (ERT) and chaperone therapy, which aim to reduce Gb3 accumulation and alleviate symptoms (Lenders & Brand, 2018; Ortiz et al., 2018) (Table 2).

Despite therapeutic advancements, significant unmet needs remain in the management of Fabry disease. Enzyme replacement therapy, while effective in slowing disease progression, is not curative and requires lifelong administration (Wanner et al., 2018). Additionally, it is less effective in reversing established organ damage (Lenders & Brand, 2018). Emerging therapies, including gene therapy and substrate reduction therapy, hold promise for addressing these limitations and improving long-term outcomes (Schuller et al., 2018; Bokhari et al., 2023).

This review aims to provide a comprehensive understanding of Fabry disease, encompassing its etiology, pathophysiology, clinical features, and diagnostic challenges. By summarizing current knowledge and exploring recent advancements, this review underscores the importance of a multidisciplinary approach in optimizing the diagnosis, treatment, and overall management of this complex disorder. Enhanced awareness among clinicians and researchers is crucial for advancing care and ultimately improving the lives of individuals affected by Fabry disease.

2. Etiology of Fabry Disease

Fabry disease arises from mutations in the gene encoding alpha-galactosidase A (α-Gal A), located on the X chromosome. These mutations result in a functional deficiency of the α-Gal A enzyme, which is the primary factor responsible for the lysosomal accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3). Over time, this progressive buildup causes cellular dysfunction and tissue damage, leading to severe systemic consequences (Wanner et al., 2018). The pathogenic accumulation of glycolipids induces endothelial cell swelling and proliferation, triggering a cascade of events that culminates in multisystem involvement, including renal, cardiac, and cerebrovascular complications.

Renal complications, including proteinuria and progressive kidney failure, typically emerge in the third or fourth decade of life. Cardiac pathology such as left ventricular hypertrophy, arrhythmias, and heart failure is common, and cerebrovascular events, including strokes, contribute to early mortality (Arends et al., 2017). Mutations associated with the classic phenotype of Fabry disease often result in a complete or near-complete loss of α-Gal A activity, leading to extensive glycolipid accumulation and multisystem involvement. Conversely, milder mutations, often missense variants, retain partial enzymatic activity and present primarily as isolated cardiac manifestations (Sweet et al., 2018). This phenotypic variability underscores the complex genotype-phenotype correlations in Fabry disease and highlights the importance of genetic analysis for accurate diagnosis and management.

Recent research has identified hundreds of mutations in the GLA gene encoding α-Gal A, broadening our understanding of Fabry disease's molecular basis (Ortiz et al., 2018). Advances in diagnostic tools, including genetic testing and biomarker assays such as plasma globotriaosylsphingosine levels, have facilitated early and precise diagnoses, particularly in patients with atypical presentations. Early identification of pathogenic mutations is critical for implementing timely therapeutic interventions, improving clinical outcomes, and preventing irreversible organ damage (Arends et al., 2017; Lenders & Brand, 2018).

3. Epidemiology of Fabry Disease

The prevalence of Fabry disease exhibits significant variability, reflecting differences in diagnostic awareness, screening practices, and study populations. Among white males, prevalence estimates range from approximately 1 in 17,000 to 1 in 117,000 (Wanner et al., 2018). Classic Fabry disease mutations, characterized by severe systemic manifestations, are estimated to occur in 1 in 22,000 to 1 in 40,000 males. Atypical presentations with milder phenotypes are more common, occurring in approximately 1 in 1,000 to 1 in 3,000 males (Chan & Adam, 2018). Female heterozygotes, who may exhibit variable symptoms due to X-chromosome inactivation, have an estimated prevalence of 1 in 6,000 to 1 in 40,000 (Lenders et al., 2016).

Fabry disease remains underdiagnosed, primarily due to its phenotypic heterogeneity and overlap with more common disorders. Systematic screening is essential, particularly in high-risk populations, such as young individuals presenting with unexplained renal dysfunction, cardiac abnormalities, or cerebrovascular events (Del Pino et al., 2018). Studies have demonstrated that Fabry disease occurs across all racial and ethnic groups, emphasizing its global relevance. Regional differences in reported prevalence likely reflect disparities in diagnostic practices rather than true population differences (Ortiz et al., 2018). Emerging newborn screening programs and genetic studies are beginning to reveal higher-than-expected prevalence rates for atypical and late-onset forms of Fabry disease, highlighting the need for enhanced awareness and diagnostic strategies (Wasserstein et al., 2019). Comprehensive epidemiological studies are essential to elucidate the true burden of Fabry disease, which remains underestimated despite its significant clinical and societal impact (Arends et al., 2017).

4. Pathophysiology of Fabry Disease

The primary metabolic defect in Fabry disease is a deficiency of lysosomal α-Gal A, an enzyme critical for breaking down Gb3. This enzymatic failure leads to the progressive accumulation of

Gb3 in lysosomes across multiple tissues and cell types, including vascular endothelial cells, renal tubular and glomerular cells, cardiac myocytes, and neurons (Lenders & Brand, 2018). This accumulation disrupts cellular homeostasis and contributes to tissue dysfunction and clinical manifestations.

The vascular system is particularly affected, with Gb3 deposition causing endothelial proliferation, vascular occlusion, and ischemic damage. These processes are implicated in the development of cerebrovascular events, including stroke, which are common in young patients with Fabry disease (Kubo, 2017). The prothrombotic state observed in these patients, marked by decreased thrombomodulin and elevated plasminogen activator inhibitor levels, further exacerbates the risk of vascular complications (Schuller et al., 2018).

Renal involvement is characterized by Gb3 accumulation within glomerular and tubular cells, leading to early proteinuria and progressive renal dysfunction. Cardiac manifestations, such as left ventricular hypertrophy, arrhythmias, and heart failure, arise from Gb3 deposition in cardiac myocytes and conduction fibers (Baig et al., 2019). Gb3 accumulation in the nervous system leads to neuropathic pain, while ocular deposition results in characteristic corneal dystrophy and lenticular opacities (Madsen et al., 2019).

A hallmark of Fabry disease pathophysiology is the systemic inflammatory state induced by Gb3 accumulation, which exacerbates tissue damage and promotes fibrosis. This inflammatory cascade involves the release of pro-inflammatory cytokines, including interleukin-6 and tumor necrosis factor-alpha, which have been detected at elevated levels in patients with Fabry disease (Ortiz et al., 2018). Additionally, the oxidative stress generated by chronic glycolipid accumulation contributes to endothelial dysfunction, further amplifying the disease's vascular and systemic impact.

Despite advancements in understanding Fabry disease's pathophysiology, certain mechanisms, such as renal sinus cyst formation and the role of secondary metabolites like globotriaosylsphingosine, remain poorly elucidated. Continued research into these pathways is essential for developing targeted therapies aimed at reducing Gb3 accumulation and mitigating its systemic effects (Arends et al., 2017; Ortiz et al., 2018).

5. Histopathology of Fabry Disease

Histological examination in Fabry disease reveals hallmark lipid accumulation across various tissues, reflecting the systemic nature of the disorder. Skin biopsies commonly demonstrate intracellular deposits of glycosphingolipids, which appear as lamellar inclusions under electron microscopy. These deposits are most pronounced in endothelial cells, smooth muscle cells, and pericytes, contributing to the vascular abnormalities characteristic of the disease (Chan & Adam, 2018). Similar lipid accumulation is observed in muscle fibers, particularly in cardiac and skeletal muscle tissues, where it disrupts normal cellular architecture and function (Sweet et al., 2018).

In the nervous system, Gb3 (globotriaosylceramide) deposition is prominent within dorsal root ganglia and autonomic neurons, correlating with neuropathic pain and autonomic dysfunction (Kubo, 2017). Renal histopathology reveals Gb3 accumulation within glomerular podocytes, tubular epithelial cells, and interstitial cells, contributing to proteinuria and progressive renal failure (Del Pino et al., 2018). Cardiovascular histopathology shows lipid deposits in cardiac myocytes, conduction fibers, and valvular fibrocytes, explaining the arrhythmias, hypertrophy, and valvular dysfunction observed in Fabry disease (Baig et al., 2019). In ocular tissues, glycosphingolipid accumulation within corneal epithelial cells results in corneal verticillata, a pathognomonic feature of the disease (Ortiz et al., 2018).

The widespread nature of lipid deposition underscores Fabry disease's systemic impact and highlights the value of tissue biopsy in confirming the diagnosis, particularly in cases with atypical presentations. Advances in histopathological techniques, including immunohistochemistry and ultrastructural analysis, have enhanced the ability to detect and characterize these deposits, providing critical insights into the disease's underlying mechanisms (Ferreira & Gahl, 2017).

6. History and Physical Examination

A thorough clinical history and physical examination are essential for diagnosing Fabry disease, given its extensive phenotypic variability. Affected individuals often report a history of heat intolerance, reduced sweating, and diminished tear production, reflecting autonomic dysfunction (Madsen et al., 2019). Gastrointestinal symptoms, including abdominal pain, cramping, and diarrhea, are common and significantly impair quality of life (Arends et al., 2017).

Cardiac and renal symptoms often dominate the clinical picture. Hypertension and proteinuria serve as early indicators of renal involvement. Patients may present with polyuria, polydipsia, and signs of progressive renal dysfunction, culminating in end-stage renal disease (Ersözlü et al., 2018). Cardiac manifestations include arrhythmias, conduction abnormalities, and valvular defects, which, if left untreated, may lead to heart failure (Lenders & Brand, 2018). Dermatological findings often include angiokeratomas—small, red-to-purple vascular lesions typically distributed in the bathing trunk region. Ophthalmological findings, such as corneal verticillata and lenticular opacities, provide important diagnostic clues (Bokhari et al., 2023).

Neurological symptoms, including acroparesthesias, are often among the earliest manifestations, particularly in male patients. Family history is critical due to the X-linked inheritance of Fabry disease. Males typically exhibit more severe symptoms, with onset in childhood or adolescence, while females may experience milder or variable presentations due to X-chromosome inactivation (Wanner et al., 2018). A high index of suspicion is warranted in individuals with a family history of renal disease, cardiac complications, or unexplained strokes, particularly at a young age. Comprehensive history-taking and targeted physical examination remain cornerstones of diagnosis.

6.1 Evaluation

Diagnosing Fabry disease requires a high index of suspicion, particularly in individuals presenting with characteristic clinical features. Diagnostic evaluations begin with a detailed personal and family history and a comprehensive physical examination. Initial tests should include a metabolic panel to assess renal function, urinalysis to detect oval fat bodies, and cardiac investigations such as electrocardiography (ECG) and echocardiography to identify conduction or structural abnormalities (Lenders et al., 2016).

Radiological assessments, including chest X-rays, computed tomography (CT), computed tomography angiography (CTA), magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), and magnetic resonance spectroscopy, are useful for evaluating patients with neurological symptoms (Fukuda et al., 2017). Definitive diagnosis hinges on demonstrating reduced alpha-galactosidase A (alpha-Gal A) activity in leukocytes or plasma. Genetic testing for GLA mutations further confirms the diagnosis (Schuller et al., 2018).

In cases where enzyme assays or genetic testing is inaccessible, tissue biopsies from the skin or kidney can aid in confirming the diagnosis. Histopathological analysis reveals glycolipid deposits, while electron microscopy of renal biopsies typically shows concentric lamellar inclusions, commonly referred to as myeloid or zebra bodies (Weidemann et al., 2018). These findings provide crucial evidence to support the diagnosis of Fabry disease.

6.2 Treatment and Management

Fabry disease currently lacks a curative treatment. Management strategies focus on supportive care, primarily through enzyme replacement therapy (ERT) using recombinant alpha- or beta-galactosidase A (Wanner et al., 2018). ERT is recommended promptly after diagnosis, irrespective of clinical symptoms in affected males and patients undergoing renal replacement therapy. For female carriers or those with partial enzyme activity, ERT is considered only if there is evident kidney, cardiac, or neurological involvement (Ortiz et al., 2018). Long-term dialysis patients also qualify for ERT to mitigate systemic complications (Lenders & Brand, 2018).

To address renal and cardiovascular risks, hypertension management involves angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (Del Pino et al., 2018). ERT is typically administered bi-weekly via intravenous infusions, with doses adjusted according to body weight. To reduce infusion-related adverse effects, a slow infusion rate over one to two hours is

Table 1. Summary of Studies on Fabry Disease and Therapeutic Approaches

Study	Author(s)	Publication Year	Focus	Key Findings
European Expert Consensus	Wanner et al.	2018	Therapeutic goals in Fabry disease	Established consensus on treatment goals for improved patient outcomes.
Effects of Enzyme Replacement	Lenders & Brand	2018	ERT and antidrug antibodies	Identified effects of antibodies on ERT efficacy in Fabry patients.
Adaptive Pathway Development	Schuller et al.	2018	Clinical pathways for Fabry disease	Suggested adaptive approaches for personalized treatment strategies.
Management and Treatment Review	Ortiz et al.	2018	Management of adult patients	Updated treatment recommendations for adult Fabry disease patients.

Table 2. Impact of Enzyme Replacement Therapy (ERT) on Fabry Disease

Author(s)	Year	Key Study Focus	Patient Group	Main Outcomes
Lenders & Brand	2018	Effects of ERT and antidrug antibodies	General population	Efficacy of ERT influenced by antibody presence.
Arends et al.	2017	Timing of ERT initiation	Men with classical Fabry	Early ERT improves biomarker levels.
Madsen et al.	2019	ERT during pregnancy	Pregnant women	Safe use of ERT documented in live births.
Ortiz et al.	2018	ERT management strategies	Adults	Recommendations for personalized therapy.

Table 3. Cardiovascular and Renal Outcomes in Fabry Disease

Study	Author(s)	Year	System Studied	Key Insights
Cardiac Involvement in Fabry Disease	Kubo	2017	Cardiac	Described cardiac manifestations and management strategies.
Cardio-Renal Syndrome and Outcomes	Siegenthaler et al.	2017	Cardio-renal	Highlighted long-term adverse outcomes in Fabry patients.
Cardiac Resynchronization Therapy	Fukuda et al.	2017	Cardiac	Demonstrated CRT benefits in cardiac Fabry patients.
Kidney Transplantation in Fabry Disease	Ersözlü et al.	2018	Renal	Long-term outcomes of kidney transplantation were favorable.

Table 4. Research Gaps and Future Directions in Fabry Disease

Area	Study/Authors	Year	Key Identified Gap	Proposed Future Direction
Newborn Screening Programs	Wasserstein et al.	2019	Limited newborn screening adoption globally	Expand newborn screening programs to detect early cases.
Female Fabry Disease Treatment	Lenders et al.	2016	Inconsistent treatment strategies for females	Standardize treatment protocols for female patients.
Pregnancy and Fabry Disease	Madsen et al.	2019	Limited data on pregnancy outcomes with ERT	Conduct longitudinal studies on pregnancy outcomes.
Adaptive Treatment Pathways	Schuller et al.	2018	Need for flexible treatment models	Develop real-world adaptive treatment frameworks.

recommended, often accompanied by premedication with antipyretics (Schuller et al., 2018).

Patients with Fabry disease who develop end-stage renal disease (ESRD) may undergo renal transplantation safely. Post-transplantation ERT is essential to prevent systemic progression and preserve organ function (Ersözlü et al., 2018). Cardiac complications, such as embolic strokes or arrhythmias, require cardiology consultation, while neurologists manage cerebrovascular risks, ensuring a comprehensive approach to care (Baig et al., 2019).

6.3 Differential Diagnosis

The differential diagnosis of Fabry disease includes conditions with overlapping clinical features. These conditions often mimic Fabry disease and include ischemic stroke, cavernous sinus syndromes, lacunar syndromes, multiple sclerosis, and other neurological disorders (Sweet et al., 2018). Accurate clinical and diagnostic evaluations are critical for distinguishing Fabry disease from these conditions.

6.4 Prognosis

The prognosis of Fabry disease varies significantly and depends on timely diagnosis and treatment initiation. The occurrence of a first stroke substantially increases the risk of recurrent cerebrovascular events, highlighting the importance of aggressive management (Bokhari et al., 2023). Heterozygous females generally exhibit milder phenotypes due to variable X-chromosome inactivation patterns, resulting in less severe systemic manifestations compared to males (Wanner et al., 2018). Early therapeutic interventions, such as ERT, improve outcomes by mitigating organ damage and preventing complications (Arends et al., 2017).

6.5 Complications

Fabry disease leads to widespread systemic complications due to glycolipid deposition in multiple tissues. Common complications include angiokeratomas, cardiomegaly, arrhythmias, acroparesthesia, hearing loss, vertigo, altered sweating, and corneal verticillata (Chan & Adam, 2018). These symptoms significantly contribute to the disease burden and necessitate multidisciplinary care to address diverse clinical challenges (Ferreira & Gahl, 2017).

6.6. ***Consultations***

Effective management of Fabry disease requires input from various specialists. Neurologists are crucial for addressing cerebrovascular complications, while cardiologists manage cardiac manifestations, such as arrhythmias and embolic strokes (Baig et al., 2019). Nephrologists oversee renal dysfunction and renal replacement therapy decisions, including transplantation (Ersözlü et al., 2018). Collaborative care is essential to ensure comprehensive management and improved outcomes for individuals with Fabry disease.

6.7 ***Other Issues***

An interprofessional team approach is vital for managing Fabry disease. This team should include specialists in neurology, ophthalmology, nephrology, cardiology, and dermatology. Patients should undergo annual evaluations to monitor emerging symptoms, including complete blood counts, renal function panels, and assessments for proteinuria (Siegenthaler et al., 2017). Cardiac surveillance using imaging and electrophysiological studies is recommended every one to two years to proactively identify complications (Kubo, 2017).

Family screening plays a pivotal role in identifying at-risk relatives, with enzymatic assays used to measure alpha-galactosidase A activity in symptomatic male and female family members (Wasserstein et al., 2019). However, there is insufficient evidence to support routine prenatal screening or ERT initiation in infants (Ortiz et al., 2018).

7. Enhancing Healthcare Team Outcomes

Fabry disease, an X-linked lysosomal storage disorder, results in lipid accumulation across tissues, causing severe complications, including stroke, myocardial infarction, renal failure, and skin lesions (Wanner et al., 2018). Early diagnosis is critical for improving prognosis, with prenatal counseling playing a vital role during pregnancy (Madsen et al., 2019).

Nurses are essential in patient education, ensuring families understand disease progression, lifestyle modifications, and follow-up care importance (Sweet et al., 2018). Pharmacists contribute to managing pharmacological interventions, such as selecting antiplatelet agents for stroke prevention, prescribing warfarin for embolic strokes, and monitoring INR levels (Arends et al., 2017). Additionally, timely ERT initiation by pharmacists significantly improves outcomes.

Physical and occupational therapists assist patients in maintaining mobility, employing assistive devices, and preserving independence in daily activities (Lenders et al., 2016). In advanced cases requiring transplantation, the transplant team ensures eligibility evaluations and postoperative care, promoting optimal patient outcomes (Ersözlü et al., 2018).

8. Outcomes of Fabry Disease and the Essential Role of Pharmacists in Management

Fabry disease is a rare, inherited disorder that presents significant clinical challenges due to its heterogeneity and life-threatening complications. The disease results from a deficiency in the enzyme alpha-galactosidase A, leading to the accumulation of glycosphingolipids in various organs, including the kidneys, heart, and nervous system (Wanner et al., 2018). Over time, these accumulations cause progressive organ damage, significantly reducing the patient's quality of life and survival rates. The life expectancy for individuals with Fabry disease is often considerably

shortened, with end-stage renal, cardiac, and hepatic complications being common causes of death. Despite the availability of enzyme replacement therapy (ERT), which helps manage the disorder, long-term survival remains low, with a notable ten-year survival rate (Lenders & Brand, 2018). These findings highlight the critical need for more effective therapeutic strategies and interventions in the treatment of Fabry disease (Table 1).

One of the key treatment modalities available is renal transplantation, which can extend survival in individuals with Fabry disease, but it is not curative. Moreover, kidney transplant recipients must adhere to lifelong immunosuppressive therapy, which carries its own set of risks and complications (Ersözlü et al., 2018). The absence of long-term randomized controlled trials and the rarity of the disease mean that much of the current clinical knowledge is based on anecdotal reports and retrospective case series (Wasserstein et al., 2019). Therefore, an interprofessional approach involving healthcare providers from diverse fields is essential for improving the quality of life of patients with Fabry disease. Nurses, therapists, and pharmacists, among other healthcare professionals, must collaborate to address the multifaceted needs of these patients, focusing on symptomatic relief, functional independence, and comprehensive support (Ortiz et al., 2018).

8.1 Role of Pharmacists in Managing Fabry Disease

Pharmacists are integral members of the multidisciplinary team that manages Fabry disease. Their expertise in pharmacotherapy plays a central role in optimizing treatment outcomes and improving patients' overall quality of life. One of the primary responsibilities of pharmacists is ensuring that enzyme replacement therapy (ERT) is properly administered. ERT, which involves infusions of alpha-galactosidase A, is crucial for patients with Fabry disease (Bokhari, Zulfiqar, & Hariz, 2023). Pharmacists are tasked with determining the appropriate dose of ERT based on patient-specific factors such as body weight, the severity of symptoms, and the extent of organ involvement. Moreover, they oversee the infusion process to minimize adverse events, including fever, chills, and hypersensitivity reactions, through strategies such as pre-administration of antipyretics (Chan & Adam, 2018).

Another significant role for pharmacists is the management of comorbidities and complications that are commonly associated with Fabry disease, particularly those affecting the cardiovascular, renal, and neurological systems. For instance, hypertension and proteinuria, which can lead to renal dysfunction, are common in Fabry disease patients. Pharmacists recommend and monitor the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to reduce proteinuria and mitigate renal disease progression (Del Pino et al., 2018). In patients at risk of thrombotic events, such as those with a history of stroke, pharmacists guide the use of antiplatelet agents. They also assist in the management of anticoagulant therapy, such as warfarin, in cases of embolic stroke, ensuring that patients maintain therapeutic international normalized ratio (INR) levels while minimizing the risk of bleeding complications (Baig et al., 2019).

Pain management is another area where pharmacists provide critical support, particularly since many patients with Fabry disease suffer from debilitating neuropathic pain. This pain is often resistant to traditional analgesics, requiring specialized treatment approaches. Pharmacists play a vital role in prescribing anticonvulsants, such as gabapentin or pregabalin, which are effective in alleviating neuropathic symptoms. Additionally, they may recommend adjunctive therapies, including tricyclic antidepressants or serotonin-norepinephrine reuptake inhibitors (SNRIs), to manage pain more effectively (Ferreira & Gahl, 2017).

Education and counseling are also essential components of the pharmacist's role. Given the chronic nature of Fabry disease, it is critical for patients and their families to understand the long-term implications of the disease, the importance of adherence to treatment plans, and the potential side effects of medications. Pharmacists provide valuable information on ERT, including its benefits, risks, and the need for regular follow-up visits to assess therapeutic efficacy (Sweet et al., 2018). They also emphasize lifestyle modifications, such as maintaining adequate hydration, avoiding nephrotoxic substances, and adhering to a balanced diet, all of which can help mitigate the progression of the disease (Lenders & Brand, 2018).

Pharmacists work closely with other healthcare professionals, such as nephrologists and cardiologists, to develop comprehensive care plans for Fabry disease patients. Their collaboration ensures that all aspects of the patient's condition are addressed. For example, pharmacists may work with nephrologists to monitor renal function and adjust medications accordingly, while cardiologists may collaborate with pharmacists to manage cardiac complications, such as arrhythmias or cardiomyopathy (Schuller et al., 2018). This interprofessional approach is essential in delivering patient-centered care that considers the individual needs of each patient.

Pharmacists are also involved in advancing research and clinical practice for Fabry disease. Their contribution to pharmacovigilance, including the reporting of adverse events and therapeutic outcomes, is crucial for improving treatment protocols and refining existing therapies. Furthermore, their involvement in clinical trials and post-marketing surveillance plays an important role in expanding the knowledge base for managing Fabry disease and identifying potential areas for therapeutic innovation (Wanner et al., 2018).

Additionally, pharmacists play a significant role in the economic and logistical aspects of Fabry disease management. ERT is an expensive therapy, and pharmacists help ensure timely access to medications by liaising with insurance providers and healthcare

institutions (Table 2). They also manage the supply chain of specialized drugs, ensuring that treatment schedules are not interrupted due to drug shortages (Ferreira & Gahl, 2017).

9. Challenges in Managing Fabry Disease

Despite the advances in treatment options, managing Fabry disease presents several challenges, especially in low-resource settings where the cost of therapies like ERT may be prohibitive. Moreover, early diagnosis remains a significant barrier, although genetic testing and newborn screening programs are making strides toward identifying the disease earlier in life (Wasserstein et al., 2019). The multidisciplinary approach to care is essential for managing the disease and improving patient outcomes, but it requires adequate resources and coordination among various healthcare providers.

10. Conclusion

In conclusion, Fabry disease is a complex, multi-systemic disorder that requires a comprehensive, patient-centered approach to management. While enzyme replacement therapy remains a cornerstone of treatment, there is a need for more accessible and cost-effective therapies, as well as continued research into gene therapy and small-molecule inhibitors as potential curative interventions. Pharmacists play a critical role in optimizing treatment regimens, educating patients, and collaborating with other healthcare providers to ensure the best possible outcomes for patients with Fabry disease. Their involvement in advancing research, improving medication adherence, and managing the economic challenges of treatment makes them indispensable members of the healthcare team.

Author contributions

M.Z.A., A.M.A., and E.H.A. conceptualized and designed the study. A.S.A. and A.A.A. conducted data collection and analysis. M.S.A. and A.L.A. contributed to data interpretation. F.H.K.A. and M.M.A. drafted the manuscript. S.A.S.A.S. and T.S.A.A.S. critically reviewed the manuscript for intellectual content. A.A.K., B.T.A., and S.R.K.A.S. provided technical support and guidance throughout the study. All authors reviewed and approved the final manuscript.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Arends, M., Wijburg, F. A., Wanner, C., Vaz, F. M., van Kuilenburg, A. B. P., Hughes, D. A., Biegstraaten, M., Mehta, A., Hollak, C. E. M., & Langeveld, M. (2017). Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Molecular Genetics and Metabolism, 121(2), 157-161.

Baig, S., Vijapurapu, R., Alharbi, F., Nordin, S., Kozor, R., Moon, J., Bembi, B., Geberhiwot, T., & Steeds, R. P. (2019). Diagnosis and treatment of the cardiovascular consequences of Fabry disease. QJM: An International Journal of Medicine, 112(1), 3-9.

Bokhari, S. R. A., Zulfiqar, H., & Hariz, A. (2023). Fabry disease. In StatPearls [Internet]. StatPearls Publishing.

Chan, B., & Adam, D. N. (2018). A review of Fabry disease. Skin Therapy Letter, 23(2), 4-6.

Del Pino, M., Andrés, A., Bernabéu, Á. Á., de Juan-Rivera, J., Fernández, E., de Dios García Díaz, J., Hernández, D., Luño, J., Fernández, I. M., Paniagua, J., Posada de la Paz, M., Rodríguez-Pérez, J. C., Santamaría, R., Torra, R., Ambros, J. T., Vidau, P., & Torregrosa, J. V. (2018). Fabry nephropathy: An evidence-based narrative review. Kidney and Blood Pressure Research, 43(2), 406-421.

Ersözlü, S., Desnick, R. J., Huynh-Do, U., Canaan-Kühl, S., Barbey, F., Genitsch, V., Mueller, T. F., Cheetham, M., Flammer, A. J., Schaub, S., & Nowak, A. (2018). Long-term outcomes of kidney transplantation in Fabry disease. Transplantation, 102(11), 1924-1933.

Ferreira, C. R., & Gahl, W. A. (2017). Lysosomal storage diseases. Translational Science of Rare Diseases, 2(1-2), 1-71.

Fukuda, Y., Onishi, T., Suzuki, A., Tanaka, H., Fukuzawa, K., Yoshida, A., Kawai, H., Hirata, K. I. (2017). Follow-up of cardiac Fabry disease treated by cardiac resynchronization therapy. CASE, 1(4), 134-137.

Kubo, T. (2017). Fabry disease and its cardiac involvement. Journal of General and Family Medicine, 18(5), 225-229.

Lenders, M., & Brand, E. (2018). Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. Journal of the American Society of Nephrology, 29(9), 2265-2278.

Lenders, M., Hennermann, J. B., Kurschat, C., Rolfs, A., Canaan-Kühl, S., Sommer, C., Üçeyler, N., Kampmann, C., Karabul, N., Giese, A. K., Duning, T., Stypmann, J., Krämer, J., Weidemann, F., Brand, S. M., Wanner, C., & Brand, E. (2016). Multicenter female Fabry study (MFFS) - Clinical survey on current treatment of females with Fabry disease. Orphanet Journal of Rare Diseases, 11(1), 88.

Madsen, C. V., Christensen, E. I., Nielsen, R., Mogensen, H., Rasmussen, Å. K., & Feldt-Rasmussen, U. (2019). Enzyme replacement therapy during pregnancy in Fabry patients: Review of published cases of live births and a new case of a severely affected female with Fabry disease and pre-eclampsia complicating pregnancy. JIMD Reports, 44, 93-101.

Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., Waldek, S., Wallace, E., Weidemann, F., & Wilcox, W. R. (2018). Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 123(4), 416-427.

Schuller, Y., Arends, M., Körver, S., Langeveld, M., & Hollak, C. E. M. (2018). Adaptive pathway development for Fabry disease: A clinical approach. Drug Discovery Today, 23(6), 1251-1257.

Siegenthaler, M., Huynh-Do, U., Krayenbuehl, P., Pollock, E., Widmer, U., Debaix, H., Olinger, E., Frank, M., Namdar, M., Ruschitzka, F., & Nowak, A. (2017). Impact of cardio-

renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. International Journal of Cardiology, 249, 261-267.

Sweet, M. E., Mestroni, L., & Taylor, M. R. G. (2018). Genetic infiltrative cardiomyopathies. Heart Failure Clinics, 14(2), 215-224.

Wanner, C., Arad, M., Baron, R., Burlina, A., Elliott, P. M., Feldt-Rasmussen, U., Fomin, V. V., Germain, D. P., Hughes, D. A., Jovanovic, A., Kantola, I., Linhart, A., Mignani, R., Monserrat, L., Namdar, M., Nowak, A., Oliveira, J. P., Ortiz, A., Pieroni, M., ... & Hilz, M. J. (2018). European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism, 124(3), 189-203.

Wasserstein, M. P., Caggana, M., Bailey, S. M., Desnick, R. J., Edelmann, L., Estrella, L., Holzman, I., Kelly, N. R., Kornreich, R., Kupchik, S. G., Martin, M., Nafday, S. M., Wasserman, R., Yang, A., Yu, C., & Orsini, J. J. (2019). The New York pilot newborn screening program for lysosomal storage diseases: Report of the first 65,000 infants. Genetics in Medicine, 21(3), 631-640.